FinancialNewsMedia.com News Commentary 

PALM BEACH, FL, Oct. 17, 2023 /PRNewswire/ -- Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US multiple myeloma therapeutics market is a growing market due to the increasing prevalence of multiple myeloma and the development of new therapies. The growth of the market is driven by factors such as an aging population, increasing prevalence of multiple myeloma, and advancements in the development of new therapies. The introduction of new therapies such as immunomodulatory drugs (IMiDs) and proteasome inhibitors has revolutionized the treatment of multiple myeloma.  A report from Insights10 projected that the U.S. Multiple Myeloma Therapeutics Market was valued at $3.5 Billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 and will reach $4.26 Billion in 2030.  Active companies in the markets this week include: Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO), Guardant Health, Inc. (NASDAQ: GH), Natera, Inc. (NASDAQ: NTRA), Quest Diagnostics Incorporated (NYSE: DGX), NeoGenomics, Inc. (NASDAQ: NEO).